### Summary of Recommendations for Adult Immunization (Age 19 years & older)

<table>
<thead>
<tr>
<th>Vaccine name and route</th>
<th>People for whom vaccination is recommended</th>
<th>Schedule for vaccination administration (any vaccine can be given with another)</th>
<th>Contraindications and precautions (mild illness is not a contraindication)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Influenza</strong>&lt;br&gt;Inactivated influenza vaccine (IIV*)&lt;br&gt;Give IM or ID (intradermally)&lt;br&gt;*includes recombinant influenza vaccine (RIV)**&lt;br&gt;Live attenuated influenza vaccine (LAIV)&lt;br&gt;Give intranasally</td>
<td>For people through age 18 years, consult “Summary of Recommendations for Child/Teen Immunization” at <a href="http://www.immunize.org/catg.d/p2010.pdf">www.immunize.org/catg.d/p2010.pdf</a>.&lt;br&gt;• Vaccination is recommended for all adults, including healthy adults ages 19–49yrs without risk factors.&lt;br&gt;• LAIV is licensed for use only for healthy nonpregnant people age 2 through 49yrs.&lt;br&gt;• Adults age 18 through 64yrs may be given any intramuscular IIV product or, alternatively, the intradermal IIV product (Fluzone Intradermal).&lt;br&gt;• Adults age 65yrs and older may be given standard-dose IIV or, alternatively, high-dose IIV (Fluzone High-Dose).&lt;br&gt;Note: Healthcare personnel who care for severely immunocompromised persons (i.e., those who require care in a protected environment) should receive IIV rather than LAIV. For information on other contraindications and precautions to LAIV, see far right column.</td>
<td>• Give 1 dose every year in the fall or winter.&lt;br&gt;• Begin vaccination services as soon as vaccine is available and continue until the supply is depleted.&lt;br&gt;• Continue to give vaccine to unvaccinated adults throughout the influenza season (including when influenza activity is present in the community) and at other times when the risk of influenza exists.&lt;br&gt;• If 2 or more of the following live virus vaccines are to be given—LAIV, MMR, Var, HZV, and/or yellow fever—they should be given on the same day. If they are not, space them by at least 28d.</td>
<td><strong>Contraindications</strong>&lt;br&gt;• Previous anaphylactic reaction to this vaccine, to any of its components, including egg protein.&lt;br&gt;• For LAIV only: pregnancy; chronic pulmonary (including asthma), cardiovascular (except hypertension), renal, hepatic, neurological/neuromuscular, hematologic, or metabolic (including diabetes) disorders; immunosuppression (including that caused by medications or HIV). Adults with egg allergy of any severity may receive RIV or, adults who experience only hives with exposure to eggs may receive other IIV with additional safety precautions (i.e., observe patient for 30 minutes after receipt of vaccine for signs of a reaction).&lt;br&gt;<strong>Precautions</strong>&lt;br&gt;• Moderate or severe acute illness.&lt;br&gt;• History of Guillain–Barré syndrome (GBS) within 6wks following previous influenza vaccination.&lt;br&gt;• For LAIV only: receipt of specific antivirals (i.e., amantadine, rimantadine, zanamivir, or oseltamivir) 48hrs before vaccination. Avoid use of these antiviral drugs for 14d after vaccination.</td>
</tr>
<tr>
<td><strong>Pneumococcal polysaccharide (PPSV)</strong>&lt;br&gt;Give IM or ID&lt;br&gt;<strong>Pneumococcal conjugate (PCV13)</strong>&lt;br&gt;Give IM</td>
<td>For people through age 18 years, consult “Summary of Recommendations for Child/Teen Immunization” <a href="http://www.immunize.org/catg.d/p2010.pdf">www.immunize.org/catg.d/p2010.pdf</a>.&lt;br&gt;• People age 65yrs and older.&lt;br&gt;• People younger than age 65yrs who have chronic illness or other risk factors, including chronic cardiac or pulmonary disease (including asthma), chronic liver disease, alcoholism, diabetes, cigarette smoking, and people living in special environments or social settings (including American Indian/Alaska Natives age 50 through 64yrs if recommended by local public health authorities).&lt;br&gt;• Those at highest risk of serious pneumococcal infection, including people who&lt;br&gt;  - Have anatomic or functional asplenia, including sickle cell disease.&lt;br&gt;  - Have an immunocompromising condition, including HIV infection, leukemia, lymphoma, Hodgkin’s disease, multiple myeloma, generalized malignancy, chronic renal failure, or nephrotic syndrome.&lt;br&gt;  - Are receiving immunosuppressive chemotherapy (including high-dose corticosteroids).&lt;br&gt;  - Have cerebrospinal fluid leaks&lt;br&gt;  - Have received an organ or bone marrow transplant.&lt;br&gt;  - Are a candidate for or recipient of a cochlear implant&lt;br&gt;For PCV13 and PPSV: Give 1 dose of PCV13 to people age 19yrs and older at highest risk of serious pneumococcal infection (see column to left). If previously vaccinated with PPSV, give PCV13 at least 12m following PPSV; if not previously vaccinated with PPSV, give PCV13 first, followed by PPSV23 in 8wks.</td>
<td></td>
<td><strong>Contraindication</strong>&lt;br&gt;Previous anaphylactic reaction to this vaccine, including (for PCV13) to any diphtheria toxoid-containing vaccine, or to any of its components.&lt;br&gt;<strong>Precaution</strong>&lt;br&gt;Moderate or severe acute illness.</td>
</tr>
</tbody>
</table>

* This document was adapted from the recommendations of the Advisory Committee on Immunization Practices (ACIP). To obtain copies of these recommendations, visit CDC’s website at www.cdc.gov/vaccines/hcp/ACIP-recs/index.html or visit the Immunization Action Coalition (IAC) website at www.immunize.org/acip. This table is revised periodically. Visit IAC’s website at www.immunize.org/adultrules to make sure you have the most current version.
### Summary of Recommendations for Adult Immunization (Age 19 years & older) (Page 2 of 4)

<table>
<thead>
<tr>
<th>Vaccine name and route</th>
<th>People for whom vaccination is recommended</th>
<th>Schedule for vaccination administration (any vaccine can be given with another)</th>
<th>Contraindications and precautions (mild illness is not a contraindication)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MMR</strong> (Measles, mumps, rubella) <strong>Give SC</strong></td>
<td>For people through age 18 years, consult “Summary of Recommendations for Child/Teen Immunization” at <a href="http://www.immunize.org/catg.d/p2010.pdf">www.immunize.org/catg.d/p2010.pdf</a>.  - People born in 1957 or later (especially those born outside the U.S.) should receive at least 1 dose of MMR if they have no laboratory evidence of immunity to each of the 3 diseases or documentation of a dose given on or after the first birthday.  - People in high-risk groups, such as healthcare personnel (paid, unpaid, or volunteer), students entering college and other post-high school educational institutions, and international travelers, should receive a total of 2 doses.  - People born before 1957 are usually considered immune, but evidence of immunity (serology or documented history of 2 doses of MMR) should be considered for healthcare personnel.  - Women of childbearing age who do not have acceptable evidence of rubella immunity or vaccination.</td>
<td>- Give 1 or 2 doses (see criteria in 1st and 2nd bullets in box to left).  - If dose #2 is recommended, give it no sooner than 4 weeks after dose #1.  - If a pregnant or childbearing-age woman is found to be rubella susceptible, give 1 dose of MMR. For pregnant women the dose should be given postpartum. This includes women who have received 1 or 2 doses of rubella-containing vaccine.  - If 2 or more of the following live virus vaccines are to be given—LAIV, MMR, Var, HZV, and/or yellow fever—they should be given on the same day. If they are not, space them by at least 28d.  - Within 72hrs of measles exposure, give 1 dose as postexposure prophylaxis to susceptible adults. <strong>Note:</strong> Routine post-vaccination serologic testing is not recommended.</td>
<td><strong>Contraindications</strong>  - Previous anaphylactic reaction to this vaccine or to any of its components.  - Pregnancy or possibility of pregnancy within 4wks.  - Severe immunodeficiency (e.g., hematologic and solid tumors; receiving chemotherapy; congenital immunodeficiency; long-term immunosuppressive therapy; or severely symptomatic HIV). <strong>Note:</strong> HIV infection is NOT a contraindication to MMR for those who are not severely immunocompromised (i.e., CD4+ T-lymphocyte counts are greater than or equal to 200 cells/μL) for 6 months.*  <strong>Precautions</strong>  - Moderate or severe acute illness.  - If blood, plasma, and/or immune globulin were given in past 11m, see ACIP’s <em>General Recommendations on Immunization</em> regarding time to wait before vaccinating.  - History of thrombocytopenia or thrombocytopenic purpura. <strong>Note:</strong> If TST (tuberculosis skin test) and MMR are both needed but not given on same day, delay TST for at least 4 wks after MMR.</td>
</tr>
<tr>
<td><strong>Varicella</strong> (chickenpox) <strong>(Var) Give SC</strong></td>
<td>For people through age 18 years, consult “Summary of Recommendations for Child/Teen Immunization” at <a href="http://www.immunize.org/catg.d/p2010.pdf">www.immunize.org/catg.d/p2010.pdf</a>.  - All adults without evidence of immunity.  <strong>Note:</strong> Evidence of immunity is defined as written documentation of 2 doses of varicella vaccine; a history of varicella disease or herpes zoster (shingles) based on healthcare-provider diagnosis; laboratory evidence of immunity or confirmation of disease; and/or birth in the U.S. before 1980, with the exceptions that follow.  - Healthcare personnel (HCP) born in the U.S. before 1980 who do not meet any of the criteria above should be tested or given the 2-dose vaccine series. If testing indicates they are not immune, give the 1st dose of varicella vaccine immediately. Give the 2nd dose 4 to 8wks later.  - Pregnant women born in the U.S. before 1980 who do not meet any of the criteria above should either 1) be tested for susceptibility during pregnancy and if found susceptible, given the 1st dose of varicella vaccine postpartum before hospital discharge, or 2) not be tested for susceptibility and given the 1st dose of varicella vaccine postpartum before hospital discharge. Give the 2nd dose 4–8wks later.</td>
<td>- Give 2 doses.  - Dose #2 is given 4–8wks after dose #1.  - If dose #2 is delayed, do not repeat dose #1. Just give dose #2.  - If 2 or more of the following live virus vaccines are to be given—LAIV, MMR, Var, HZV, and/or yellow fever—they should be given on the same day. If they are not, space them by at least 28d.  - May use as postexposure prophylaxis if given within 5d. <strong>Note:</strong> Routine post-vaccination serologic testing is not recommended.</td>
<td><strong>Contraindications</strong>  - Previous anaphylactic reaction to this vaccine or to any of its components.  - Pregnancy or possibility of pregnancy within 4wks.  - People on long-term immunosuppressive therapy or who are immunocompromised because of malignancy and primary or acquired immunodeficiency, including HIV/AIDS (although vaccination may be considered if CD4+ T-lymphocyte counts are greater than or equal to 200 cells/μL). See MMWR 2007;56,RR-4).  <strong>Precautions</strong>  - Moderate or severe acute illness.  - If blood, plasma, and/or immune globulin were given in past 11m, see ACIP’S <em>General Recommendations on Immunization</em> regarding time to wait before vaccinating.  - History of thrombocytopenia or thrombocytopenic purpura. <strong>Note:</strong> If TST (tuberculosis skin test) and MMR are both needed but not given on same day, delay TST for at least 4 wks after MMR.</td>
</tr>
<tr>
<td><strong>Human papilloma-virus</strong> (HPV) <strong>(HPV2, Cervarix) (HPV4, Gardasil) Give IM</strong></td>
<td>For people through age 18 years, consult “Summary of Recommendations for Child/Teen Immunization” at <a href="http://www.immunize.org/catg.d/p2010.pdf">www.immunize.org/catg.d/p2010.pdf</a>.  - All previously unvaccinated women through age 26yrs and men through age 21yrs.  - All previously unvaccinated men through age 26yrs who 1) have sex with men or 2) are immunocompromised as a result of infection (including HIV), disease, or medications, or who lack either of the preceding risk factors but want to be vaccinated.</td>
<td>- Give 3 doses on a 0, 2, 6m schedule. Use either HPV2 or HPV4 for women, and only HPV4 for men.  - There must be at least 4wks between doses #1 and #2 and at least 12wks between doses #2 and #3. Overall, there must be at least 24wks between doses #1 and #3. If possible, use the same vaccine product for all three doses.</td>
<td><strong>Precautions</strong>  - Moderate or severe acute illness.  - Pregnancy.</td>
</tr>
</tbody>
</table>
### Summary of Recommendations for Adult Immunization (Age 19 years & older)

#### Vaccine name and route

<table>
<thead>
<tr>
<th>Vaccine name and route</th>
<th>People for whom vaccination is recommended</th>
<th>Schedule for vaccination administration (any vaccine can be given with another)</th>
<th>Contraindications and precautions (mild illness is not a contraindication)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hepatitis A</strong> (HepA)</td>
<td>Give IM Brands may be used interchangeably.</td>
<td>• Give 2 doses, spaced 6–18m apart (depending on brand). &lt;br&gt;• If dose #2 is delayed, do not repeat dose #1. Just give dose #2.</td>
<td><strong>Contraindication</strong> Previous anaphylactic reaction to this vaccine or to any of its components. &lt;br&gt;<strong>Precautions</strong> Moderate or severe acute illness.</td>
</tr>
<tr>
<td><strong>Hepatitis B</strong> (HepB)</td>
<td>Give IM Brands may be used interchangeably.</td>
<td>• Give 3 doses on a 0, 1, 6m schedule. &lt;br&gt;• Alternative timing options for vaccination include 0, 2, 4m; 0, 1, 4m; and 0, 1, 2, 12m (Engerix brand only). &lt;br&gt;• There must be at least 4wks between doses #1 and #2, and at least 8wks between doses #2 and #3. &lt;br&gt;<strong>Schedule for those who have fallen behind:</strong> If the series is delayed between doses, DO NOT start the series over. Continue from where the schedule was interrupted.</td>
<td><strong>Contraindication</strong> Previous anaphylactic reaction to this vaccine or to any of its components. &lt;br&gt;<strong>Precaution</strong> Moderate or severe acute illness.</td>
</tr>
<tr>
<td><strong>Inactivated Polio</strong> (IPV)</td>
<td>Give IM or SC</td>
<td>• Refer to ACIP recommendations* regarding unique situations, schedules, and dosing information.</td>
<td><strong>Contraindication</strong> Previous anaphylactic reaction to this vaccine or to any of its components. &lt;br&gt;<strong>Precautions</strong> Moderate or severe acute illness. &lt;br&gt;<strong>Pregnancy.</strong></td>
</tr>
<tr>
<td><strong>Hib</strong> (Haemophilus influenzae type b)</td>
<td>Give IM</td>
<td>• Give 1 dose of any Hib conjugate vaccine to adults in categories 1 or 2 (see 2nd bullet in column to left) if no history of previous Hib vaccine. &lt;br&gt;• For HSCT patients, regardless of Hib vaccination history, give 3 doses, at least 4wks apart, beginning 6–12m after transplant.</td>
<td><strong>Contraindication</strong> Previous anaphylactic reaction to this vaccine or to any of its components. &lt;br&gt;<strong>Precautions</strong> Moderate or severe acute illness.</td>
</tr>
</tbody>
</table>

---

**Note:**
- People who anticipate close personal contact with an international adoptee from a country of high or intermediate endemicity during the first 60 days following the adoptee’s arrival in the U.S.
- Adults age 40yrs or younger with recent (within 2 wks) exposure to HAV. For people older than age 40yrs with recent (within 2 wks) exposure to HAV, immune globulin is preferred over HepA vaccine.
- Children aged 11–12yrs with recent (within 2 wks) exposure to HAV may be given HepB vaccine if they are completing a series of either HepA or HepB vaccination.
- Inactivated Polio (IPV) is given by the oral route. Depending on the human immunodeficiency virus (HIV) risk category, either oral or inactivated IPV may be used. Refer to ACIP’s recommendations regarding unique situations, schedules, and dosing information.
- Hib vaccine is not routinely recommended for U.S. residents age 18yrs and older. Adults living in the U.S. who never received or completed a primary series of polio vaccine need not be vaccinated unless they intend to travel to areas where exposure to wild-type virus is likely. Adults with documented prior vaccination can receive 1 booster dose if traveling to polio endemic areas or to areas where the risk of exposure is high.
- Contraindications include moderate or severe acute illness.

---

**For Twinrix (hepatitis A and B combination vaccine [GSK]) for patients age 18yrs and older only:** give 3 doses on a 0, 1, 6m schedule. There must be at least 4wks between doses #1 and #2, and at least 5m between doses #2 and #3. An alternative schedule can also be used at 0, 7d, 21 to 30d, and a booster at 12m.
<table>
<thead>
<tr>
<th>Vaccine name and route</th>
<th>People for whom vaccination is recommended</th>
<th>Schedule for vaccination administration (any vaccine can be given with another)</th>
<th>Contraindications and precautions (mild illness is not a contraindication)</th>
</tr>
</thead>
</table>
- People with anatomic or functional asplenia or persistent complement component deficiency.  
- People who travel to or reside in countries in which meningococcal disease is hyperendemic or epidemic (e.g., the “meningitis belt” of Sub-Saharan Africa).  
- Microbiologists routinely exposed to isolates of *N. meningitidis*.  
- First year college students through age 21yrs who live in a residence hall; see 5th bullet in the box to the right for details.                                                                 | • Give 2 initial doses of MCV4 separated by 2m to adults 55yrs and younger with risk factors listed in 1st bullet in column to left or if vaccinating adults with HIV infection in this age group.  
- Give 1 initial dose to all other adults with risk factors (see 2nd–4th bullets in column to left).  
- Give booster doses every 5yrs to adults with continuing risk (see 1st–3rd bullets in column to left).  
- MCV4 is preferred over MPSV4 for people age 55yrs and younger. For people age 56yrs and older who anticipate multiple doses (see 1st–3rd bullets in column to left) or who have received MCV4 previously, use MCV4. For all others, use MPSV4.  
- For first year college students age 19 through 21yrs living in a residence hall, give 1 initial dose if unvaccinated and give booster dose if most recent dose was given when younger than 16yrs.                                                                 | Contraindication  
Previous anaphylactic reaction to this vaccine or to any of its components.  
Precaution  
Moderate or severe acute illness.                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
- All people who lack written documentation of a primary series consisting of at least 3 doses of tetanus- and diphtheria-toxoid-containing vaccine.  
- A booster dose of Td or Tdap may be needed for wound management, so consult ACIP recommendations.*  
**For Tdap only:**  
- Adults who have not already received Tdap.  
- Healthcare personnel of all ages.  
- Give Td to pregnant women during each pregnancy (preferred during 27–36 weeks’ gestation), regardless of the interval since prior Td or Tdap.                                                                 | • For people who are unvaccinated or behind, complete the primary Td series (spaced at 0, 1–2m, 6–12m intervals); substitute a one-time dose of Tdap for one of the doses in the series, preferably the first.  
- Give Tdap booster every 10yrs after the primary series has been completed.  
- Tdap should be given regardless of interval since previous Td.                                                                 | Contraindications  
• Previous anaphylactic reaction to this vaccine or to any of its components.  
• For Tdap only, history of encephalopathy not attributable to an identifiable cause, within 7d following DTP/DTaP, or Tdap.  
**Precautions**  
• Moderate or severe acute illness.  
• Guillain-Barré syndrome within 6wks following previous dose of tetanus-toxoid-containing vaccine.  
• History of arthus reaction following a prior dose of tetanus- or diphtheria toxoid-containing vaccine (including MCV4); defer vaccination until at least 10yrs have elapsed since the last tetanus toxoid-containing vaccine.  
• For pertussis-containing vaccines only, progressive or unstable neurologic disorder, uncontrolled seizures, or progressive encephalopathy until a treatment regimen has been established and the condition has stabilized.                                                                                                                                                                                                 |
- People age 60yrs and older.  
**Note:** Do not test people age 60 years or older for varicella immunity prior to zoster vaccination. Persons born in the U.S. prior to 1980 can be presumed to be immune to varicella for the purpose of zoster vaccination, regardless of their recollection of having had chickenpox.  
- Give 1-time dose if unvaccinated, regardless of previous history of herpes zoster (shingles) or chickenpox.  
- If 2 or more of the following live virus vaccines are to be given—MMR, Var, HZV, and/or yellow fever—they should be given on the same day. If they are not, space them by at least 28d.                                                                 | • Give 2 initial doses of MCV4 separated by 2m to adults 55yrs and younger with risk factors listed in 1st bullet in column to left or if vaccinating adults with HIV infection in this age group.  
- Give 1 initial dose to all other adults with risk factors (see 2nd–4th bullets in column to left).  
- Give booster doses every 5yrs to adults with continuing risk (see 1st–3rd bullets in column to left).  
- MCV4 is preferred over MPSV4 for people age 55yrs and younger. For people age 56yrs and older who anticipate multiple doses (see 1st–3rd bullets in column to left) or who have received MCV4 previously, use MCV4. For all others, use MPSV4.  
- For first year college students age 19 through 21yrs living in a residence hall, give 1 initial dose if unvaccinated and give booster dose if most recent dose was given when younger than 16yrs.                                                                 | Contraindications  
• Previous anaphylactic reaction to this vaccine or to any of its components.  
• For Tdap only, history of encephalopathy not attributable to an identifiable cause, within 7d following DTP/DTaP, or Tdap.  
**Precautions**  
• Moderate or severe acute illness.  
• Guillain-Barré syndrome within 6wks following previous dose of tetanus-toxoid-containing vaccine.  
• History of arthus reaction following a prior dose of tetanus- or diphtheria toxoid-containing vaccine (including MCV4); defer vaccination until at least 10yrs have elapsed since the last tetanus toxoid-containing vaccine.  
• For pertussis-containing vaccines only, progressive or unstable neurologic disorder, uncontrolled seizures, or progressive encephalopathy until a treatment regimen has been established and the condition has stabilized.  
• For Td, Tdap only:  
- Adults who have not already received Tdap.  
- Healthcare personnel of all ages.  
- Give Td to pregnant women during each pregnancy (preferred during 27–36 weeks’ gestation), regardless of the interval since prior Td or Tdap.                                                                 |